chronic lymphocytic leukemia (Cancer)
Information
- Disease name
- chronic lymphocytic leukemia
- Disease ID
- DOID:1040
- Description
- "A lymphocytic leukemia characterized by over production of B-cells and their accumulation in bone marrow and blood." [url:http\://en.wikipedia.org/wiki/B-cell_chronic_lymphocytic_leukemia, url:http\://www.cancer.gov/dictionary?cdrid=346545]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04657094 | Active, not recruiting | Phase 2 | Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | March 16, 2021 | December 30, 2024 |
| NCT04722172 | Active, not recruiting | Phase 2 | A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL | May 21, 2021 | February 2025 |
| NCT03737981 | Active, not recruiting | Phase 3 | Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia | January 31, 2019 | June 1, 2027 |
| NCT04624633 | Active, not recruiting | Phase 2 | Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL | December 15, 2020 | January 1, 2030 |
| NCT03708003 | Active, not recruiting | Phase 2 | Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL | March 11, 2019 | December 2026 |
| NCT03701282 | Active, not recruiting | Phase 3 | Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia | February 12, 2019 | May 7, 2028 |
| NCT04159779 | Active, not recruiting | A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece | January 13, 2020 | June 30, 2026 | |
| NCT03671590 | Active, not recruiting | Phase 1 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | September 10, 2018 | June 1, 2024 |
| NCT02717611 | Active, not recruiting | Phase 2 | A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy | March 8, 2016 | September 1, 2026 |
| NCT02629809 | Active, not recruiting | Phase 2 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | March 18, 2016 | March 31, 2025 |
| NCT04155710 | Active, not recruiting | Phase 1/Phase 2 | Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL | February 19, 2020 | September 2025 |
| NCT03609593 | Active, not recruiting | Phase 2 | Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia | November 12, 2018 | December 2025 |
| NCT03560752 | Active, not recruiting | Phase 1 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant | August 20, 2018 | June 18, 2024 |
| NCT03524235 | Active, not recruiting | Phase 1 | Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL | July 18, 2018 | November 2031 |
| NCT00039676 | Active, not recruiting | Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer | July 8, 2002 | ||
| NCT04716075 | Active, not recruiting | Phase 2 | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) | August 19, 2019 | September 30, 2024 |
| NCT04545333 | Active, not recruiting | The clonoSEQ® Watch Registry | October 13, 2020 | December 2024 | |
| NCT00586391 | Active, not recruiting | Phase 1 | CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL | February 2009 | July 2029 |
| NCT02553447 | Active, not recruiting | N/A | Cholecalciferol in Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency | October 19, 2015 | March 24, 2025 |
| NCT04060277 | Active, not recruiting | Phase 2 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation | November 27, 2019 | April 7, 2030 |
| NCT03513562 | Active, not recruiting | Phase 2 | Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations | March 26, 2019 | December 31, 2024 |
| NCT03480360 | Active, not recruiting | Phase 3 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression | March 28, 2018 | September 13, 2025 |
| NCT02537613 | Active, not recruiting | Phase 1 | A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | December 2015 | January 2029 |
| NCT04512105 | Active, not recruiting | Phase 1 | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia | December 2, 2020 | June 1, 2024 |
| NCT02518555 | Active, not recruiting | Phase 2 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | January 12, 2016 | December 31, 2024 |
| NCT04018248 | Active, not recruiting | Phase 1 | BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) | April 21, 2020 | March 2024 |
| NCT04008706 | Active, not recruiting | Phase 3 | Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients | September 17, 2019 | September 1, 2025 |
| NCT03913949 | Active, not recruiting | Phase 1 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies | June 3, 2019 | December 31, 2025 |
| NCT02514083 | Active, not recruiting | Phase 2 | A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL | December 9, 2015 | October 23, 2028 |
| NCT03467867 | Active, not recruiting | Phase 2 | A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | April 26, 2018 | October 2024 |
| NCT01351896 | Active, not recruiting | Phase 2 | Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | November 2, 2011 | December 31, 2024 |
| NCT03447808 | Active, not recruiting | Phase 1 | Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | August 16, 2018 | December 31, 2024 |
| NCT02506933 | Active, not recruiting | Phase 2 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant | November 5, 2015 | December 30, 2024 |
| NCT03422393 | Active, not recruiting | Phase 1 | Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | May 1, 2018 | August 2028 |
| NCT04501939 | Active, not recruiting | Phase 2 | Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax | August 6, 2020 | July 22, 2025 |
| NCT04938141 | Active, not recruiting | MEOI and HRQoL in CLL Patients Treated With BTKis | October 7, 2021 | September 5, 2024 | |
| NCT03893682 | Active, not recruiting | Phase 1 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | April 30, 2019 | December 2024 |
| NCT03336333 | Active, not recruiting | Phase 3 | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL | October 31, 2017 | September 2026 |
| NCT02477696 | Active, not recruiting | Phase 3 | Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL) | July 28, 2015 | January 3, 2028 |
| NCT03333486 | Active, not recruiting | Phase 2 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | December 7, 2017 | August 28, 2024 |
| NCT03328273 | Active, not recruiting | Phase 1 | A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | January 31, 2018 | June 28, 2024 |
| NCT02475681 | Active, not recruiting | Phase 3 | Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL | June 26, 2015 | September 30, 2025 |
| NCT03280160 | Active, not recruiting | Phase 2 | Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab | September 7, 2017 | September 2022 |
| NCT03207555 | Active, not recruiting | Phase 2 | Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL) | May 23, 2018 | August 31, 2025 |
| NCT04657224 | Active, not recruiting | Phase 1 | A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | February 25, 2021 | July 11, 2025 |
| NCT04688385 | Active, not recruiting | Phase 1 | Personalized Multi-peptide Vaccination in CLL Patients | December 23, 2020 | December 31, 2024 |
| NCT03884998 | Active, not recruiting | Phase 1 | Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | February 26, 2019 | July 16, 2024 |
| NCT03844048 | Active, not recruiting | Phase 3 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | September 6, 2019 | May 27, 2025 |
| NCT03204188 | Active, not recruiting | Phase 2 | Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | September 22, 2017 | December 31, 2026 |
| NCT03162536 | Active, not recruiting | Phase 1/Phase 2 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | June 26, 2017 | September 12, 2025 |
| NCT05999877 | Active, not recruiting | PICAROS - Acalabrutinib RWE on 1L CLL in Spain | July 11, 2023 | December 31, 2026 | |
| NCT02427451 | Active, not recruiting | Phase 1/Phase 2 | Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia | August 3, 2015 | December 31, 2024 |
| NCT00709033 | Active, not recruiting | Phase 1 | T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLL | July 2009 | April 2027 |
| NCT02970318 | Active, not recruiting | Phase 3 | A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL | February 2, 2017 | September 6, 2027 |
| NCT04887259 | Active, not recruiting | Phase 1/Phase 2 | Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML | July 12, 2021 | December 30, 2024 |
| NCT01496976 | Active, not recruiting | Phase 2 | Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL | March 30, 2012 | August 4, 2024 |
| NCT04852822 | Active, not recruiting | Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | March 18, 2021 | July 1, 2024 | |
| NCT00719888 | Active, not recruiting | Phase 2 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease | November 18, 2005 | December 22, 2024 |
| NCT02414022 | Active, not recruiting | Economic Analysis of Alliance A041202 CLL Study | April 15, 2015 | January 30, 2025 | |
| NCT02396134 | Active, not recruiting | Phase 2 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | May 21, 2015 | December 31, 2024 |
| NCT04666038 | Active, not recruiting | Phase 3 | Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | March 9, 2021 | May 2027 |
| NCT02339922 | Active, not recruiting | Phase 2 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | May 19, 2016 | January 6, 2031 |
| NCT05437250 | Active, not recruiting | National Acalabrutinib Observational Study | September 13, 2022 | November 15, 2026 | |
| NCT02337829 | Active, not recruiting | Phase 2 | Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL | January 12, 2015 | April 1, 2026 |
| NCT02924402 | Active, not recruiting | Phase 1 | Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies | October 2016 | January 2025 |
| NCT02315768 | Active, not recruiting | Phase 1/Phase 2 | Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients. | August 26, 2015 | November 2023 |
| NCT05023980 | Active, not recruiting | Phase 3 | A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | September 23, 2021 | May 2026 |
| NCT02827617 | Active, not recruiting | Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia | June 1, 2016 | December 31, 2024 | |
| NCT02825836 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects | August 26, 2016 | December 1, 2025 |
| NCT04464200 | Active, not recruiting | Phase 1 | 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers | July 6, 2020 | July 2026 |
| NCT03836261 | Active, not recruiting | Phase 3 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL | February 25, 2019 | January 6, 2027 |
| NCT04312841 | Active, not recruiting | Phase 2 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | September 15, 2020 | December 31, 2024 |
| NCT05972577 | Active, not recruiting | N/A | Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study | June 2, 2021 | December 31, 2024 |
| NCT02296918 | Active, not recruiting | Phase 1 | Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL | December 22, 2014 | September 6, 2027 |
| NCT02290951 | Active, not recruiting | Phase 1 | Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies | January 9, 2015 | December 2, 2025 |
| NCT02756897 | Active, not recruiting | Phase 2 | Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia | July 7, 2016 | July 1, 2024 |
| NCT02251548 | Active, not recruiting | Phase 2 | A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia | October 2014 | January 2026 |
| NCT04809467 | Active, not recruiting | Phase 1/Phase 2 | A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) | September 16, 2021 | December 15, 2024 |
| NCT02194387 | Active, not recruiting | N/A | Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members | September 17, 2014 | September 30, 2025 |
| NCT03740529 | Active, not recruiting | Phase 1/Phase 2 | A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | November 16, 2018 | January 2028 |
| NCT02158091 | Active, not recruiting | Phase 1/Phase 2 | A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL | June 27, 2014 | July 2025 |
| NCT04754035 | Active, not recruiting | Phase 2 | Clinical Study With Ibrutinib and Venetoclax for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia | November 8, 2017 | September 1, 2025 |
| NCT02157324 | Active, not recruiting | Phase 1 | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | August 18, 2014 | May 31, 2026 |
| NCT02135133 | Active, not recruiting | Phase 2 | A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL | June 2014 | August 2024 |
| NCT04240704 | Active, not recruiting | Phase 1 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | September 7, 2020 | September 30, 2024 |
| NCT02131584 | Active, not recruiting | Phase 2 | Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia | September 2, 2014 | September 30, 2026 |
| NCT02048813 | Active, not recruiting | Phase 3 | Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | February 20, 2014 | December 31, 2024 |
| NCT02029443 | Active, not recruiting | Phase 1/Phase 2 | ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia | January 30, 2014 | September 6, 2027 |
| NCT00850057 | Completed | Phase 1 | Pharmacodynamic (PD) Study of Intranodal Adenovirus-CD154 (Ad-ISF35) in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | February 2006 | October 2009 |
| NCT00854646 | Completed | Phase 1 | Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS) | October 2008 | December 2015 |
| NCT00860457 | Completed | Phase 2 | Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL) | February 2008 | February 2012 |
| NCT00864942 | Completed | Phase 1 | Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL) | February 2009 | October 2014 |
| NCT00868413 | Completed | Phase 1 | Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia | November 2009 | May 2013 |
| NCT00873457 | Completed | Phase 2 | Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | August 2009 | April 2013 |
| NCT00880815 | Completed | Phase 1 | Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant | February 17, 2009 | May 28, 2019 |
| NCT00889031 | Completed | Protocol to Obtain Blood Samples for Leukemia Research | April 2009 | March 9, 2018 | |
| NCT00898079 | Completed | Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | October 13, 2003 | June 30, 2018 | |
| NCT00918723 | Completed | Phase 1/Phase 2 | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | June 2009 | October 2016 |
| NCT00931645 | Completed | Phase 3 | Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia | April 2001 | December 2008 |
| NCT00934986 | Completed | N/A | Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia | March 2008 | September 2010 |
| NCT00974233 | Completed | Phase 2 | Study of Bendamustine/Rituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed/Refractory CLL and SLL | October 2009 | April 2015 |
| NCT00975975 | Completed | Phase 2 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | September 2009 | November 2013 |
| NCT00990587 | Completed | Phase 1 | Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy | October 2009 | |
| NCT01002755 | Completed | Phase 2 | Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | January 19, 2010 | January 31, 2018 |
| NCT01011894 | Completed | Phase 2 | Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age | November 6, 2009 | February 23, 2016 |
| NCT01013441 | Completed | Phase 1 | CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia | March 2009 | December 2018 |
| NCT01021358 | Completed | Phase 1 | A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax). | January 2010 | |
| NCT01024010 | Completed | Phase 2 | Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | March 2010 | September 28, 2017 |
| NCT01028430 | Completed | B Cell Repertoires in Chronic Lymphocytic Leukemia and Aging | July 1998 | September 2023 | |
| NCT01030536 | Completed | Phase 1/Phase 2 | Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) | February 15, 2010 | March 4, 2013 |
| NCT01030913 | Completed | B-type Chronic Lymphocytic Leukemia (B-CLL) Subgroups: Maturation Stage and Gene Expression | December 1999 | September 2023 | |
| NCT01066663 | Completed | Phase 1/Phase 2 | Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | March 2010 | January 2023 |
| NCT01081015 | Completed | Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry | March 19, 2010 | December 31, 2017 | |
| NCT01082939 | Completed | Phase 2 | Cyclophosphamide, Fludarabine, Alemtuzumab, and Rituximab (CFAR) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | December 2002 | January 2011 |
| NCT01087151 | Completed | Phase 2 | A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) | August 2010 | June 2012 |
| NCT01088048 | Completed | Phase 1 | Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia | March 25, 2010 | April 28, 2015 |
| NCT01098188 | Completed | Phase 1 | LFB-R603 Dose Finding in Patients With Advanced Stage B-Chronic Lymphocytic Leukemia | November 2008 | August 2011 |
| NCT01109264 | Completed | Phase 2 | Bendamustine Hydrochloride Injection for Initial Treatment of Chronic Lymphocytic Leukemia | March 2010 | August 2013 |
| NCT01110850 | Completed | Direct Measurement of Leukemic Cell Turnover (Synthesis and Removal) in Patients With Chronic Lymphocytic Leukemia (CLL) Using Deuterated Water | June 2001 | May 23, 2018 | |
| NCT01110863 | Completed | Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects | December 2005 | February 12, 2016 | |
| NCT01113632 | Completed | Phase 2 | Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | July 2010 | August 2016 |
| NCT01118234 | Completed | Phase 3 | Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) | December 2009 | July 2019 |
| NCT01120457 | Completed | Phase 1 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | August 2010 | November 2014 |
| NCT01123356 | Completed | Phase 2 | Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab | May 2010 | June 2013 |
| NCT01125176 | Completed | Phase 2 | Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL | March 30, 2012 | December 29, 2020 |
| NCT01133743 | Completed | Phase 2 | Open-Label Study of Lenalidomide in Combination With Oral Dexamethasone in the Treatment of Previously Untreated, Symptomatic Patients With Chronic Lymphocytic Leukemia | May 2010 | December 2016 |
| NCT01149915 | Completed | Phase 1 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias | June 2010 | August 2013 |
| NCT01161511 | Completed | Phase 1 | Safety and Tolerability of XmAb®5574 in Chronic Lymphocytic Leukemia | September 2010 | January 2013 |
| NCT01181258 | Completed | Phase 2 | Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies | August 2010 | July 2016 |
| NCT01181271 | Completed | Phase 2 | Tandem Auto-Allo Transplant for Lymphoma | August 2010 | February 2016 |
| NCT01185262 | Completed | Phase 1 | Activity & Safety Study of Lenalidomide & Rituximab as Non-chemotherapy Based Therapy on Chronic Lymphocytic Leukemia | April 2009 | September 2013 |
| NCT01199575 | Completed | Phase 2 | Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | August 2010 | February 22, 2022 |
| NCT01231412 | Completed | Phase 3 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | November 2010 | June 30, 2017 |
| NCT01243190 | Completed | Phase 2 | Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | March 2011 | March 28, 2023 |
| NCT01251575 | Completed | Phase 2 | Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant | December 1, 2010 | February 11, 2019 |
| NCT01255644 | Completed | Phase 4 | Antiviral Treatment of Chronic Lymphocytic Leukemia | December 2010 | July 2015 |
| NCT01272817 | Completed | N/A | Nonmyeloablative Allogeneic Transplant | October 2001 | October 2015 |
| NCT01290302 | Completed | Phase 1 | Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia | October 2010 | |
| NCT01290549 | Completed | Phase 1 | A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma | March 22, 2011 | November 18, 2014 |
| NCT01300026 | Completed | Phase 1 | AMG 319 Lymphoid Malignancy FIH | April 2011 | December 2016 |
| NCT01310101 | Completed | Phase 2 | Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | April 2011 | February 2015 |
| NCT01326702 | Completed | Phase 1/Phase 2 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | July 2011 | April 2015 |
| NCT01328626 | Completed | Phase 1 | A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma | May 23, 2011 | May 8, 2020 |
| NCT01350245 | Completed | Phase 2 | Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor | July 2010 | May 2014 |
| NCT01351935 | Completed | Phase 1 | Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | July 18, 2011 | June 26, 2015 |
| NCT01353625 | Completed | Phase 1 | Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies. | April 25, 2011 | March 12, 2021 |
| NCT01364363 | Completed | N/A | Unrelated Donor Stem Cell Transplantation | March 2005 | July 2015 |
| NCT01369849 | Completed | Phase 1/Phase 2 | Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | September 2011 | February 2014 |
| NCT01392079 | Completed | Phase 2 | Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine | February 2008 | March 2016 |
| NCT01393366 | Completed | N/A | Facing Obstacles to RDI (Relative Dose Intensity) Through Telephone Intervention Strategy | September 2011 | December 2016 |
| NCT01399840 | Completed | Phase 1 | Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies | June 30, 2011 | May 31, 2014 |
| NCT01400685 | Completed | Phase 1 | Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL | December 2012 | January 2018 |
| NCT01408563 | Completed | Phase 2 | Reduced Intensity Double Umbilical Cord Blood Transplantation | December 2011 | June 2017 |
| NCT01410513 | Completed | Phase 1 | Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia | December 2011 | May 2014 |
| NCT01423032 | Completed | Phase 2/Phase 3 | Bendamustine Versus Fludarabine in Chronic Lymphocytic Leukemia (CLL) | September 2001 | May 2009 |
| NCT01444716 | Completed | Phase 2 | Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia | December 15, 2011 | June 11, 2020 |
| NCT01445132 | Completed | Phase 1 | Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation | January 11, 2007 | April 24, 2013 |
| NCT01455051 | Completed | Phase 2 | Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation | October 2011 | October 2017 |
| NCT01459211 | Completed | Phase 2 | Pilot Study to Establish Safety & Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL) | May 2012 | February 2016 |
| NCT01460134 | Completed | Phase 1 | A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers | October 2011 | October 16, 2017 |
| NCT01460238 | Completed | Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia | October 2011 | May 2018 | |
| NCT01474681 | Completed | Phase 1/Phase 2 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | January 9, 2012 | October 3, 2016 |
| NCT01484015 | Completed | Phase 1 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | February 2011 | October 2012 |
| NCT01486797 | Completed | Phase 2 | NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) | March 2012 | April 2017 |
| NCT01497496 | Completed | Phase 2 | Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | January 26, 2012 | March 20, 2020 |
| NCT01500083 | Completed | Phase 3 | Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia | March 2012 | June 2013 |
| NCT01515176 | Completed | Phase 1/Phase 2 | Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia | January 2012 | July 19, 2016 |
| NCT01527045 | Completed | Phase 2 | Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies | September 25, 2012 | April 2019 |
| NCT01534715 | Completed | Phase 1 | IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | January 2012 | July 2016 |
| NCT01539512 | Completed | Phase 3 | A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) | April 2012 | April 2014 |
| NCT01556776 | Completed | Phase 3 | A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy | July 20, 2012 | January 14, 2021 |
| NCT01557777 | Completed | Phase 2 | Open-label Extension Study of Navitoclax in Subjects With Chronic Lymphocytic Leukemia (CLL) | June 2012 | July 2013 |
| NCT01558167 | Completed | Phase 1/Phase 2 | A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia | February 2011 | June 2015 |
| NCT01567709 | Completed | Phase 1 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | April 16, 2012 | March 29, 2018 |
| NCT01569295 | Completed | Phase 3 | Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela ) | June 15, 2012 | June 10, 2019 |
| NCT01572662 | Completed | Phase 2 | Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning | April 11, 2012 | August 11, 2022 |
| NCT01610180 | Completed | Phase 2 | Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) | June 2012 | June 30, 2018 |
| NCT01611090 | Completed | Phase 3 | A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | September 19, 2012 | January 23, 2019 |
| NCT01627054 | Completed | Phase 2 | A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia | August 27, 2012 | February 13, 2015 |
| NCT01634217 | Completed | Phase 1 | Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation | November 8, 2013 | December 1, 2018 |
| NCT01650727 | Completed | Phase 1 | A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974) | October 2012 | October 2013 |
| NCT00001586 | Completed | Phase 2 | Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis | September 1997 | November 2011 |
| NCT00001637 | Completed | Phase 2 | Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults | September 29, 1997 | December 28, 2016 |
| NCT00001830 | Completed | Phase 1 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | July 20, 1999 | May 19, 2015 |
| NCT00001873 | Completed | Phase 2 | The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers | February 22, 1999 | June 13, 2017 |
| NCT00021749 | Completed | Phase 1/Phase 2 | Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia | January 2001 | |
| NCT00036023 | Completed | Phase 2 | Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies | ||
| NCT00036257 | Completed | Phase 1 | Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia | March 2002 | April 2003 |
| NCT00038025 | Completed | Phase 2 | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies | September 6, 1994 | November 29, 2006 |
| NCT00038831 | Completed | Phase 1/Phase 2 | Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS | May 2001 | October 2006 |
| NCT00046488 | Completed | Phase 1 | Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL) | September 2002 | March 2010 |
| NCT00058656 | Completed | Phase 1/Phase 2 | Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients | March 2003 | |
| NCT00060424 | Completed | Phase 2 | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia | March 2003 | September 22, 2010 |
| NCT00071396 | Completed | Phase 2 | Campath-1H Plus Rituximab for CD52- and CD20- Positive Refractory or Relapsed Chronic Lymphoid Disorders | October 2002 | August 2007 |
| NCT00073489 | Completed | Phase 2 | A Pilot Study of OSI-461 in Patients With Chronic Lymphocytic Leukemia (CLL) | May 2001 | December 2003 |
| NCT00078234 | Completed | Phase 1/Phase 2 | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia | November 2003 | September 2010 |
| NCT00086203 | Completed | Phase 2 | Study of Talabostat and Rituximab in Advanced Chronic Lymphocytic Leukemia (CLL) | September 2007 | |
| NCT00090051 | Completed | Phase 3 | FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients | July 31, 2003 | May 31, 2012 |
| NCT00096161 | Completed | Phase 2 | Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant | May 2003 | August 2015 |
| NCT00102661 | Completed | Phase 2 | Continuous Infusion of Campath-1H Followed by Subcutaneous Injections in Previously Treated Patients With Chronic Lymphocytic Leukemia | October 2002 | September 2006 |
| NCT00103558 | Completed | Phase 1/Phase 2 | Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | March 2004 | March 2010 |
| NCT00104858 | Completed | Phase 2 | Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | December 2004 | March 30, 2018 |
| NCT00145652 | Completed | Phase 3 | Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. | December 2003 | December 2005 |
| NCT00159003 | Completed | Analysis of Genetic Factors Related to Predisposition and Prognosis of Hematological Malignancies in Israel | January 1, 1998 | July 1, 2017 | |
| NCT00193518 | Completed | Phase 2 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | April 2004 | April 2006 |
| NCT00201682 | Completed | Phase 1/Phase 2 | Etanercept and Rituximab in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | October 2002 | August 2009 |
| NCT00233506 | Completed | Phase 1 | A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated | July 2004 | June 2011 |
| NCT00254410 | Completed | Phase 2 | FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years | March 14, 2005 | September 14, 2017 |
| NCT00262782 | Completed | Phase 3 | Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | April 1997 | June 2010 |
| NCT00262795 | Completed | Phase 3 | Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | September 2003 | October 2005 |
| NCT00267059 | Completed | Phase 2 | Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL) | December 2005 | August 2009 |
| NCT00274963 | Completed | Phase 2 | Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | October 2004 | October 2009 |
| NCT00274989 | Completed | Phase 2 | Bendamustine and Rituximab in Treating Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia | November 2005 | March 2011 |
| NCT00275015 | Completed | Phase 2 | Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia | January 1998 | April 2012 |
| NCT00275054 | Completed | Phase 3 | Rituximab, Fludarabine, and Cyclophosphamide or Observation Alone in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia | October 2005 | June 2015 |
| NCT00275431 | Completed | Phase 2 | Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies | November 2005 | December 2008 |
| NCT00276809 | Completed | Phase 2 | Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | June 2001 | September 2004 |
| NCT00276848 | Completed | Phase 3 | Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia | July 1999 | July 2007 |
| NCT00280241 | Completed | Phase 2 | Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia | June 2004 | January 2013 |
| NCT00281892 | Completed | Phase 3 | Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia | September 2004 | October 2010 |
| NCT00281983 | Completed | Phase 1/Phase 2 | Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | June 2000 | July 2010 |
| NCT00285103 | Completed | Phase 1/Phase 2 | SPC2996 in Chronic Lymphocytic Leukaemia | June 2005 | December 2007 |
| NCT00286780 | Completed | Phase 2 | Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia | January 2006 | November 2007 |
| NCT00290004 | Completed | Phase 1/Phase 2 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | November 2005 | February 2007 |
| NCT00309842 | Completed | Phase 2 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases | July 28, 2005 | November 22, 2019 |
| NCT00309881 | Completed | Phase 2 | Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) | April 2003 | March 2011 |
| NCT00330252 | Completed | Phase 1 | Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL | May 2006 | January 2014 |
| NCT00378534 | Completed | Phase 2 | Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | September 2006 | April 2014 |
| NCT00381004 | Completed | Phase 2 | FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia | September 2006 | December 2014 |
| NCT00419250 | Completed | Phase 1 | A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia | December 1, 2006 | June 1, 2010 |
| NCT00428233 | Completed | Phase 1 | Banking of Chronic Lymphocytic Leukemia Tumor Cells for Vaccine Generation | November 2006 | June 2014 |
| NCT00438854 | Completed | Phase 2 | Dasatinib in Relapsed Chronic Lymphocytic Leukemia | December 2006 | March 2013 |
| NCT00442130 | Completed | Phase 1 | Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination | February 2007 | April 2020 |
| NCT00446342 | Completed | Phase 1 | Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies | February 2007 | March 2009 |
| NCT00448019 | Completed | Phase 2 | FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL) | February 2007 | October 2014 |
| NCT00466895 | Completed | Phase 1 | Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia. | April 2007 | July 2016 |
| NCT00481091 | Completed | Phase 1/Phase 2 | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | July 25, 2007 | May 12, 2022 |
| NCT00481858 | Completed | Kinetic Biomarker for Chronic Lymphocytic Leukemia Prognosis | July 2005 | January 2011 | |
| NCT00504972 | Completed | Phase 1 | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies | June 2007 | October 7, 2015 |
| NCT00513175 | Completed | Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia | October 2001 | November 2007 | |
| NCT00514696 | Completed | Phase 2 | Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia | February 2007 | April 2009 |
| NCT00525603 | Completed | Phase 2 | CFAR Study in Patients With Chronic Lymphocytic Leukemia | June 2005 | July 2011 |
| NCT00535873 | Completed | Phase 2 | Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older | October 2007 | February 2013 |
| NCT00536341 | Completed | Phase 1/Phase 2 | Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL) | January 2008 | November 2016 |
| NCT00562770 | Completed | Phase 2 | Oral Valganciclovir Versus Valacyclovir | September 2003 | July 2006 |
| NCT00569842 | Completed | Investigation of the Cylex® ImmuKnow® Assay | November 2007 | December 2012 | |
| NCT00571662 | Completed | Phase 2 | Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant | December 8, 2000 | December 30, 2008 |
| NCT00593944 | Completed | Phase 1 | Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL) | August 2008 | May 2010 |
| NCT00600964 | Completed | Phase 1 | A Phase I/II Study of GX15-070MS in Untreated CLL | September 2004 | January 2006 |
| NCT00608361 | Completed | Phase 1 | Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery | October 2008 | August 2014 |
| NCT00632359 | Completed | Phase 2 | Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual Disease | February 2008 | October 2015 |
| NCT00634881 | Completed | Phase 1/Phase 2 | Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia | November 2003 | February 17, 2012 |
| NCT00683046 | Completed | Phase 2 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | November 2001 | December 2014 |
| NCT00709592 | Completed | Phase 2 | Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT | July 21, 2008 | June 28, 2017 |
| NCT00714103 | Completed | Phase 1 | 8-Chloro-Adenosine in Chronic Lymphocytic Leukemia | June 2008 | October 2016 |
| NCT00727415 | Completed | Phase 1/Phase 2 | Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to Therapy | February 2008 | January 2016 |
| NCT00735930 | Completed | Phase 1 | Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | August 2008 | November 2014 |
| NCT00743028 | Completed | Phase 1 | Assess the Oral Bioavailability of New ABT-263 Formulations | August 2008 | |
| NCT00749502 | Completed | Phase 1 | A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) | September 2008 | June 2013 |
| NCT00759603 | Completed | Phase 2 | Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | September 2008 | July 2014 |
| NCT00759798 | Completed | Phase 2 | Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL) | August 13, 2008 | July 22, 2020 |
| NCT00769522 | Completed | Phase 3 | FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | October 2, 2008 | January 2018 |
| NCT00772486 | Completed | Phase 1 | A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL | September 2008 | April 2013 |
| NCT00772811 | Completed | Phase 2 | Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma | July 2001 | December 2010 |
| NCT00779883 | Completed | Phase 1 | A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) | June 2006 | March 2008 |
| NCT00783588 | Completed | Phase 1 | A Phase I Extension Trial of Repeated Infusions of ISF35 | May 2007 | September 2008 |
| NCT00794820 | Completed | Phase 2 | Fludarabine, Cyclophosphamide, and Rituximab - High Dose Frontline | December 2003 | December 2014 |
| NCT00807677 | Completed | Phase 1 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies | March 2009 | March 2013 |
| NCT00828282 | Completed | Phase 1 | High-dose HMG-CoA Inhibitor Simvastatin Relapsed CLL | March 2009 | April 2014 |
| NCT01671904 | Completed | Phase 1 | A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL) | January 13, 2014 | August 11, 2020 |
| NCT01681563 | Completed | Phase 2 | Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia | September 2011 | December 2016 |
| NCT01682616 | Completed | Phase 1 | A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | July 25, 2012 | June 23, 2022 |
| NCT01696461 | Completed | Phase 2 | A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor | May 2013 | August 2016 |
| NCT01699152 | Completed | Phase 1 | Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | September 2012 | May 2016 |
| NCT01703364 | Completed | Phase 1/Phase 2 | Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | June 2012 | October 2015 |
| NCT01716208 | Completed | Phase 2 | Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma | January 14, 2013 | October 1, 2020 |
| NCT01722487 | Completed | Phase 3 | Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL | March 2013 | May 2015 |
| NCT01724346 | Completed | Phase 3 | Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | August 28, 2012 | August 17, 2023 |
| NCT01760655 | Completed | Phase 2 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies | December 24, 2012 | December 5, 2022 |
| NCT01767766 | Completed | Phase 1 | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies | January 7, 2013 | February 2018 |
| NCT01832922 | Completed | Phase 1 | BR in Patients With CLL With Comorbidities and/or Renal Dysfunction | April 2013 | November 28, 2016 |
| NCT01841489 | Completed | Phase 1 | A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics | May 2013 | October 2013 |
| NCT01848145 | Completed | Phase 2 | Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia | July 2013 | March 2017 |
| NCT01868893 | Completed | Phase 2 | An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia | August 2013 | January 2014 |
| NCT01871675 | Completed | Phase 1 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | May 2013 | June 2016 |
| NCT01889186 | Completed | Phase 2 | A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion | June 27, 2013 | December 15, 2020 |
| NCT01892618 | Completed | Phase 3 | Pneumococcal Vaccine in Untreated CLL Patients | August 2013 | December 2015 |
| NCT01905943 | Completed | Phase 3 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | November 4, 2013 | October 8, 2018 |
| NCT01930162 | Completed | Phase 2 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant | October 7, 2014 | August 29, 2016 |
| NCT01951885 | Completed | Phase 3 | Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention | July 7, 2014 | August 11, 2021 |
| NCT01973387 | Completed | Phase 3 | A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma | October 28, 2013 | August 11, 2017 |
| NCT02004522 | Completed | Phase 3 | A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) | November 2013 | June 2021 |
| NCT02005471 | Completed | Phase 3 | A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | March 17, 2014 | August 3, 2022 |
| NCT02006485 | Completed | Phase 1 | Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies | December 13, 2013 | October 2019 |
| NCT02013128 | Completed | Phase 1/Phase 2 | Ublituximab + Ibrutinib in Select B-cell Malignancies | January 6, 2014 | December 2015 |
| NCT02015208 | Completed | Phase 1/Phase 2 | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | April 2014 | July 2015 |
| NCT02042911 | Completed | Phase 2 | Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia | January 2013 | June 2015 |
| NCT02049515 | Completed | Phase 3 | A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 | December 2013 | June 12, 2020 |
| NCT02057185 | Completed | Occupational Status and Hematological Disease | September 8, 2014 | November 11, 2015 | |
| NCT02071225 | Completed | Phase 2 | A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia | April 9, 2014 | November 19, 2018 |
| NCT02080884 | Completed | An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia | June 24, 2014 | December 19, 2016 | |
| NCT02100852 | Completed | Phase 1 | TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL) | March 12, 2014 | November 2017 |
| NCT02110394 | Completed | Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia | June 2012 | August 2015 | |
| NCT02129582 | Completed | Phase 1 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies | November 5, 2014 | March 5, 2020 |
| NCT02141282 | Completed | Phase 2 | A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy | September 10, 2014 | December 22, 2021 |
| NCT02144623 | Completed | Early Phase 1 | Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia | January 2015 | February 6, 2017 |
| NCT02208037 | Completed | Phase 2 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | August 2014 | October 2017 |
| NCT02222688 | Completed | Phase 1 | UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia | August 8, 2014 | May 1, 2018 |
| NCT02242045 | Completed | Phase 1 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) | October 1, 2014 | October 17, 2017 |
| NCT02264574 | Completed | Phase 3 | A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | October 6, 2014 | September 3, 2019 |
| NCT02294552 | Completed | Phase 2 | Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | October 2014 | November 2017 |
| NCT02301156 | Completed | Phase 3 | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | January 27, 2015 | April 1, 2020 |
| NCT02316197 | Completed | Phase 1 | Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia | December 31, 2014 | June 29, 2017 |
| NCT02320487 | Completed | Phase 2 | A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | March 31, 2015 | February 6, 2019 |
| NCT02340780 | Completed | Phase 2 | Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia | April 27, 2015 | April 28, 2020 |
| NCT02381899 | Completed | Observational Study in CLL Patients Receiving BR | September 2014 | December 2018 | |
| NCT02424968 | Completed | Phase 2 | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma | June 2015 | April 2021 |
| NCT02481297 | Completed | Phase 2 | Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients | June 23, 2015 | August 15, 2019 |
| NCT02491398 | Completed | Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia | February 2016 | January 2017 | |
| NCT02530515 | Completed | Phase 2 | Ex Vivo-activated Autologous Lymph Node Lymphocytes in Treating Patients With Chronic Lymphocytic Leukemia | December 18, 2015 | April 30, 2018 |
| NCT02535286 | Completed | Phase 1 | Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation | September 18, 2015 | November 4, 2021 |
| NCT02556931 | Completed | Phase 2 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies | December 2015 | April 2021 |
| NCT02581007 | Completed | Phase 2 | Reduced Intensity Conditioning Transplant Using Haploidentical Donors | October 26, 2015 | December 28, 2020 |
| NCT02582320 | Completed | Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program | March 2016 | October 3, 2018 | |
| NCT02593123 | Completed | Phase 2 | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis | November 4, 2015 | March 18, 2022 |
| NCT02619604 | Completed | N/A | A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia | May 2016 | February 2017 |
| NCT02639910 | Completed | Phase 2 | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi | November 2016 | December 2021 |
| NCT02661035 | Completed | Phase 2 | Allo HSCT Using RIC for Hematological Diseases | March 9, 2017 | May 29, 2023 |
| NCT02669017 | Completed | Phase 1 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | March 2016 | February 21, 2019 |
| NCT02689141 | Completed | Phase 2 | Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO) | February 4, 2016 | February 6, 2020 |
| NCT02742090 | Completed | Phase 2 | Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy | April 21, 2016 | June 10, 2021 |
| NCT02756611 | Completed | Phase 3 | A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) | June 22, 2016 | March 11, 2022 |
| NCT02767388 | Completed | Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery | September 1, 2016 | March 15, 2018 | |
| NCT02801578 | Completed | Phase 2/Phase 3 | A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL) | July 6, 2016 | January 28, 2019 |
| NCT02860676 | Completed | Phase 1 | Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 | November 3, 2016 | May 22, 2018 |
| NCT02863718 | Completed | Phase 3 | Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression | April 30, 2014 | July 11, 2022 |
| NCT02890758 | Completed | Phase 1 | Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 | May 22, 2018 | February 17, 2023 |
| NCT02891590 | Completed | Phase 1 | Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas | September 2016 | February 2019 |
| NCT02900716 | Completed | Phase 1 | Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas | September 2016 | November 23, 2020 |
| NCT02910583 | Completed | Phase 2 | Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) | September 28, 2016 | March 27, 2024 |
| NCT02915224 | Completed | A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities | November 23, 2016 | June 8, 2021 | |
| NCT02950051 | Completed | Phase 3 | Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation | December 13, 2016 | February 29, 2024 |
| NCT02968563 | Completed | Phase 2 | Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | December 13, 2016 | January 14, 2021 |
| NCT02983617 | Completed | Phase 2 | Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) | April 6, 2017 | October 1, 2020 |
| NCT03019055 | Completed | Phase 1 | Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell | October 16, 2017 | August 24, 2021 |
| NCT03056339 | Completed | Phase 1/Phase 2 | Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies | June 21, 2017 | March 6, 2023 |
| NCT03059251 | Completed | Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina | August 31, 2017 | March 30, 2019 | |
| NCT03076437 | Completed | Phase 1/Phase 2 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | January 15, 2016 | December 31, 2019 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT03263637 | Completed | Phase 1 | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | October 24, 2017 | September 30, 2021 |
| NCT03310190 | Completed | Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice | January 10, 2018 | April 30, 2022 | |
| NCT03316209 | Completed | Identification of Occupational Exposures in Acute Hematologic Malignancy | April 27, 2017 | March 26, 2019 | |
| NCT03374137 | Completed | Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia | March 9, 2018 | November 10, 2022 | |
| NCT03436524 | Completed | A Prognostic Tool for Early Stage CLL | March 1, 2018 | February 28, 2020 | |
| NCT03454165 | Completed | Phase 1 | A Study of BNC105P Combined With Ibrutinib | March 9, 2018 | January 14, 2021 |
| NCT03528941 | Completed | The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib | November 28, 2018 | June 30, 2021 | |
| NCT03545035 | Completed | Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC Study | February 6, 2019 | October 28, 2020 | |
| NCT03734016 | Completed | Phase 3 | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia | November 1, 2018 | February 28, 2024 |
| NCT03734601 | Completed | Phase 2 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | November 5, 2018 | November 17, 2020 |
| NCT03833180 | Completed | Phase 1 | A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) | March 14, 2019 | December 18, 2023 |
| NCT03870633 | Completed | Assessment of Financial Difficulty in Participants With Chronic Lymphocytic Leukemia and Multiple Myeloma | March 15, 2019 | May 1, 2023 | |
| NCT03892044 | Completed | Phase 1 | Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma | November 5, 2019 | February 14, 2024 |
| NCT03939234 | Completed | Phase 2 | Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. | April 26, 2019 | March 15, 2021 |
| NCT04030195 | Completed | Phase 1/Phase 2 | Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL | March 24, 2020 | June 24, 2021 |
| NCT04282343 | Completed | N/A | DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer | February 25, 2020 | October 21, 2022 |
| NCT04666025 | Completed | SARS-CoV-2 Donor-Recipient Immunity Transfer | September 23, 2020 | May 5, 2023 | |
| NCT04774744 | Completed | N/A | Effect of Digital Health Coaching Program on Self-efficacy and Patient Reported Outcomes of Patients With Newly Diagnosed Acute Myeloid Leukemia or Chronic Lymphocytic Leukemia | March 17, 2020 | September 13, 2023 |
| NCT04858568 | Completed | Immune Responses to COVID-19 Vaccination in Lymphoma Patients | March 11, 2021 | January 31, 2024 | |
| NCT04950452 | Completed | N/A | Exercise Training to Promote Resilience to Chronic Lymphocytic Leukemia | August 22, 2018 | January 6, 2020 |
| NCT04964908 | Completed | Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic Leukemia | December 3, 2021 | August 31, 2023 | |
| NCT05028374 | Completed | Phase 2 | COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies | August 17, 2021 | November 2, 2021 |
| NCT05093192 | Completed | N/A | Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia | October 1, 2021 | December 6, 2022 |
| NCT05260203 | Completed | N/A | MargheRITA (Remote Intelligence for Therapeutic Adherence) | June 4, 2022 | January 16, 2023 |
| NCT05555979 | Completed | A Study to Assess Change in Patient Experience in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets + Intravenous Rituximab or Bruton's Tyrosine Kinase Inhibitors Tablets in the United Kingdom | December 14, 2022 | April 10, 2024 | |
| NCT05928156 | Completed | N/A | Multiple Myeloma/Chronic Lymphocytic Leukemia Coach RCT | December 17, 2020 | September 19, 2021 |
| NCT06211413 | Enrolling by invitation | Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors | February 7, 2024 | August 2025 | |
| NCT01804686 | Enrolling by invitation | Phase 3 | A Long-term Extension Study of PCI-32765 (Ibrutinib) | September 9, 2013 | January 29, 2027 |
| NCT05899543 | Not yet recruiting | Determining Clinical Study Experiences of Chronic Lymphocytic Leukemia Patients | July 2024 | July 2026 | |
| NCT05718986 | Not yet recruiting | Familial B-cell Lymphoproliferative Disorders | June 2024 | December 2040 | |
| NCT06428019 | Not yet recruiting | Phase 3 | A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | June 6, 2024 | October 21, 2026 |
| NCT06291220 | Not yet recruiting | Phase 1 | A Study Assessing Adverse Event and How Oral ABBV-453 Moves Through the Body in Adult Participants With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | June 2, 2024 | July 21, 2029 |
| NCT06364033 | Not yet recruiting | N/A | Biological and Clinical Efficacy of Shingrix in Patients With CLL | August 2024 | October 2028 |
| NCT04790045 | Not yet recruiting | Phase 4 | Lymph Node Microenvironment Modifications in Patients With CLL Treated With Venetoclax-based Regimens | November 1, 2023 | December 31, 2026 |
| NCT06224309 | Not yet recruiting | Preliminary Assessment of [18F]BL40 in PET/CT Scans | May 2024 | October 2025 | |
| NCT05287984 | Not yet recruiting | Phase 2 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL | March 22, 2022 | November 29, 2024 |
| NCT06367374 | Not yet recruiting | Phase 2 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | May 30, 2024 | July 30, 2030 |
| NCT05360758 | Not yet recruiting | Ibrutinib Adapted to Response in Patients With CLL | June 1, 2023 | December 1, 2025 | |
| NCT06084923 | Not yet recruiting | Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression | May 2024 | May 2026 | |
| NCT04980859 | Not yet recruiting | Phase 3 | Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 Mutation | September 1, 2021 | September 1, 2025 |
| NCT06416267 | Not yet recruiting | Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL) | August 2024 | December 2040 | |
| NCT03153202 | Recruiting | Phase 1/Phase 2 | Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) | July 14, 2017 | December 2025 |
| NCT04356846 | Recruiting | Phase 1 | A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma | May 1, 2020 | December 1, 2023 |
| NCT01787409 | Recruiting | N/A | Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency | March 6, 2013 | March 28, 2025 |
| NCT05478512 | Recruiting | Phase 2 | Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL | July 21, 2023 | July 2027 |
| NCT05643235 | Recruiting | N/A | Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors | January 1, 2023 | December 1, 2030 |
| NCT04494503 | Recruiting | Phase 1/Phase 2 | Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL | August 31, 2020 | December 2025 |
| NCT05317936 | Recruiting | Phase 2 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | November 16, 2022 | October 1, 2027 |
| NCT04502030 | Recruiting | Phase 3 | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) | October 5, 2020 | October 2025 |
| NCT04502394 | Recruiting | Phase 1/Phase 2 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | February 23, 2021 | March 2024 |
| NCT05672355 | Recruiting | Phase 2 | A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia | August 1, 2023 | January 12, 2026 |
| NCT04505254 | Recruiting | Phase 2 | Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia | August 25, 2020 | June 1, 2024 |
| NCT03197259 | Recruiting | Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study | January 1, 2017 | August 1, 2026 | |
| NCT05556720 | Recruiting | Phase 3 | Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial | December 1, 2022 | December 31, 2025 |
| NCT04553692 | Recruiting | Phase 1 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers | September 23, 2020 | August 2027 |
| NCT04560322 | Recruiting | Phase 2 | Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL | October 19, 2020 | March 1, 2025 |
| NCT04578613 | Recruiting | Phase 3 | ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL | January 8, 2021 | June 30, 2025 |
| NCT05677919 | Recruiting | Phase 2 | Pirtobrutinib and Venetoclax Combined With Minimal Residual Disease Detection for Previously Untreated Chronic Lymphocytic Leukemia | January 31, 2023 | July 19, 2025 |
| NCT04616274 | Recruiting | Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia | July 1, 2020 | December 31, 2025 | |
| NCT06362044 | Recruiting | A Study to Assess Frequency of Undetectable Minimal Residual Disease (uMRD) in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Venetoclax Tablets ± Intravenously (IV) Infused Rituximab in Routine Clinical Practice in Japan | June 7, 2023 | December 31, 2024 | |
| NCT04629729 | Recruiting | Phase 1 | FT819 in Subjects With B-cell Malignancies | July 26, 2021 | September 30, 2039 |
| NCT04640909 | Recruiting | N/A | Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients | October 1, 2021 | October 2024 |
| NCT05544019 | Recruiting | Phase 1 | Study of SGR-1505 in Mature B-Cell Neoplasms | April 10, 2023 | March 2026 |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT04935684 | Recruiting | Phase 2 | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation | December 20, 2022 | December 2027 |
| NCT04663100 | Recruiting | N/A | Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence | February 8, 2021 | December 31, 2023 |
| NCT04908228 | Recruiting | Phase 2 | Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL | December 13, 2021 | September 15, 2027 |
| NCT06250465 | Recruiting | AGMT Austrian CLL (Chronic Lymphocytic Leukemia) Registry | March 24, 2022 | December 31, 2027 | |
| NCT05971251 | Recruiting | Phase 1 | Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia | December 18, 2023 | December 31, 2028 |
| NCT04679012 | Recruiting | Phase 2 | Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation | September 24, 2021 | September 2026 |
| NCT04904588 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide | September 30, 2021 | July 2024 |
| NCT04684563 | Recruiting | Phase 1 | huCART19-IL18 in NHL/CLL Patients | May 6, 2021 | May 2036 |
| NCT04867915 | Recruiting | Study on the Diagnosis and Management of CLL in Italy by GIMEMA | October 13, 2021 | October 2026 | |
| NCT06333262 | Recruiting | Phase 2 | Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia | April 22, 2024 | February 1, 2029 |
| NCT05694312 | Recruiting | Phase 2 | Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL | November 24, 2023 | November 2026 |
| NCT04844528 | Recruiting | Phase 2 | Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC) | August 5, 2021 | August 1, 2026 |
| NCT04732845 | Recruiting | Phase 1 | Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies | April 26, 2021 | December 1, 2024 |
| NCT04746950 | Recruiting | ALICIA (Acalabrutinib in CLL Therapy) | February 3, 2021 | December 31, 2025 | |
| NCT04843904 | Recruiting | Phase 1 | Safe Accelerated Venetoclax Escalation in CLL | April 14, 2021 | June 2, 2030 |
| NCT04771507 | Recruiting | Phase 1/Phase 2 | A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) | February 23, 2018 | December 1, 2027 |
| NCT04771572 | Recruiting | Phase 1 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | August 23, 2021 | October 1, 2025 |
| NCT04785989 | Recruiting | In Vivo Metabolic Profiling of CLL (Chronic Lymphocytic Leukemia) | June 13, 2022 | October 2024 | |
| NCT03314974 | Recruiting | Phase 2 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | March 30, 2018 | November 10, 2025 |
| NCT05281809 | Recruiting | Phase 2 | Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia | April 19, 2022 | December 1, 2037 |
| NCT05458297 | Recruiting | Phase 2 | A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) | July 21, 2022 | April 26, 2027 |
| NCT05417165 | Recruiting | Phase 2 | Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia | September 29, 2023 | December 31, 2025 |
| NCT06396611 | Recruiting | N/A | Exercise as Intervention in Chronic Lymphocytic Leukemia | September 1, 2023 | August 31, 2025 |
| NCT06001385 | Recruiting | Phase 2 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | December 8, 2023 | June 30, 2026 |
| NCT03375619 | Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells | December 1, 2017 | January 1, 2035 | |
| NCT02846623 | Recruiting | Phase 2 | Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome | January 31, 2017 | February 28, 2025 |
| NCT05405309 | Recruiting | Phase 1/Phase 2 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia | September 23, 2022 | August 15, 2027 |
| NCT06014762 | Recruiting | Phase 1 | P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | April 16, 2024 | March 2041 |
| NCT05694364 | Recruiting | Phase 1 | Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies | January 25, 2023 | January 2026 |
| NCT05254743 | Recruiting | Phase 3 | A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | July 22, 2022 | August 2028 |
| NCT05702853 | Recruiting | Phase 1/Phase 2 | Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL | November 6, 2023 | December 30, 2026 |
| NCT06037018 | Recruiting | Phase 1 | Safety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies | August 7, 2023 | March 2026 |
| NCT05602363 | Recruiting | Phase 1 | AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | August 1, 2023 | September 2027 |
| NCT05246345 | Recruiting | Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia | March 7, 2022 | March 2027 | |
| NCT03492125 | Recruiting | Phase 1/Phase 2 | A Study Of The Selective PKC-β Inhibitor MS- 553 | May 25, 2018 | June 15, 2024 |
| NCT01853631 | Recruiting | Phase 1 | Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) | February 2014 | February 2036 |
| NCT03501576 | Recruiting | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma | April 6, 2018 | October 22, 2024 | |
| NCT05197192 | Recruiting | Phase 3 | A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL | April 19, 2022 | February 2027 |
| NCT05718869 | Recruiting | Phase 2 | Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study | May 18, 2023 | October 19, 2025 |
| NCT03516617 | Recruiting | Phase 2 | Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | September 10, 2018 | March 15, 2026 |
| NCT06043674 | Recruiting | Phase 2 | A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation | January 22, 2024 | January 15, 2033 |
| NCT03529227 | Recruiting | Gazyva Infusion Reaction Investigation | March 31, 2018 | April 30, 2025 | |
| NCT03534323 | Recruiting | Phase 1/Phase 2 | Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS | July 12, 2018 | July 1, 2026 |
| NCT06059391 | Recruiting | Phase 2 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | August 30, 2024 | January 1, 2028 |
| NCT05400122 | Recruiting | Phase 1 | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer | September 9, 2022 | June 1, 2026 |
| NCT05739227 | Recruiting | Early Phase 1 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | March 1, 2023 | May 2025 |
| NCT05797233 | Recruiting | Phase 1 | Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies | August 28, 2023 | December 30, 2029 |
| NCT05183854 | Recruiting | Phase 2 | Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial | January 7, 2022 | January 7, 2027 |
| NCT05803395 | Recruiting | Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. | September 12, 2023 | September 2024 | |
| NCT03622788 | Recruiting | Phase 1/Phase 2 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | August 8, 2019 | December 1, 2025 |
| NCT05153330 | Recruiting | Phase 1 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | January 24, 2022 | March 31, 2025 |
| NCT05147467 | Recruiting | Phase 2 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | December 28, 2021 | December 2024 |
| NCT05140369 | Recruiting | CLL Therapy Approaches in Russia | October 29, 2021 | December 31, 2026 | |
| NCT03676504 | Recruiting | Phase 1/Phase 2 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | September 7, 2018 | April 1, 2024 |
| NCT05388006 | Recruiting | Phase 2 | Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | June 15, 2022 | November 15, 2025 |
| NCT06379282 | Recruiting | N/A | Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia | October 14, 2022 | August 1, 2026 |
| NCT06125795 | Recruiting | A Study to Assess Change in Functioning and Health Related Quality of Life in Adult Participants With Chronic Lymphocytic Leukemia (CLL) Receiving Oral Treatments in Routine Clinical Practice in Spain | November 6, 2023 | April 30, 2025 | |
| NCT05844033 | Recruiting | Biomarker for Infection Risk in CLL and MM | August 1, 2023 | March 31, 2027 | |
| NCT02952508 | Recruiting | Phase 2 | Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | July 26, 2017 | June 30, 2025 |
| NCT03765177 | Recruiting | Phase 1/Phase 2 | CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies | October 16, 2019 | October 31, 2037 |
| NCT05878184 | Recruiting | Phase 1 | Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT) | May 2, 2023 | December 2027 |
| NCT06136559 | Recruiting | Phase 3 | A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | December 13, 2023 | September 30, 2032 |
| NCT05091424 | Recruiting | Phase 1 | A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | March 7, 2022 | October 8, 2029 |
| NCT01962636 | Recruiting | N/A | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases | December 2016 | October 2025 |
| NCT05031897 | Recruiting | Phase 2 | Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant | October 25, 2021 | October 1, 2024 |
| NCT06151730 | Recruiting | Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study | January 5, 2024 | December 1, 2025 | |
| NCT05618028 | Recruiting | Phase 1 | Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | April 4, 2023 | June 27, 2027 |
| NCT06170671 | Recruiting | REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in Romania | December 13, 2023 | September 30, 2028 | |
| NCT05020678 | Recruiting | Phase 1 | NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers | August 20, 2021 | December 2038 |
| NCT01890486 | Recruiting | The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | May 21, 2001 | December 2025 | |
| NCT06205498 | Recruiting | Acalabrutinib Real World Italian obSErvational Study -ARISE | August 8, 2023 | February 28, 2030 | |
| NCT05020392 | Recruiting | Phase 3 | Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma | September 14, 2021 | October 13, 2024 |
| NCT03960840 | Recruiting | Phase 1/Phase 2 | Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL | June 26, 2019 | June 30, 2027 |
| NCT05006716 | Recruiting | Phase 1/Phase 2 | A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | September 13, 2021 | March 31, 2028 |
| NCT03980002 | Recruiting | Phase 2 | A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL | May 15, 2019 | December 30, 2027 |
| NCT03986034 | Recruiting | Phase 2 | Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) | June 26, 2019 | December 3, 2024 |
| NCT05371808 | Recruiting | Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: | January 27, 2023 | October 1, 2028 | |
| NCT05879133 | Recruiting | N/A | HEALTH4CLL2: A Randomized Waitlist Control Trial of Behavioral Interventions in Patients With Chronic Lymphocytic Leukemia | May 17, 2023 | July 3, 2025 |
| NCT04028531 | Recruiting | Understanding Chronic Lymphocytic Leukemia | September 29, 1999 | September 29, 2026 | |
| NCT05212233 | Recruiting | Financial Difficulty in Patients With Blood Cancer | January 27, 2022 | December 31, 2024 | |
| NCT05512390 | Recruiting | Phase 1 | A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | April 26, 2023 | February 7, 2027 |
| NCT04965493 | Recruiting | Phase 3 | A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | September 20, 2021 | January 2027 |
| NCT05336812 | Recruiting | Phase 2 | Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia | September 13, 2022 | December 31, 2024 |
| NCT05624554 | Recruiting | Phase 3 | A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008) | March 16, 2023 | March 17, 2031 |
| NCT05943496 | Recruiting | Phase 1 | Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia | October 2, 2023 | January 1, 2027 |
| NCT05950997 | Recruiting | N/A | A Single Arm Study of Acalabrutinib Conbimed With Obinutuzumab in Chinese Patients With Previously Untreated CLL | April 16, 2024 | September 30, 2026 |
| NCT04167683 | Recruiting | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant | October 1, 2023 | December 31, 2026 | |
| NCT05334069 | Recruiting | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | August 1, 2022 | February 2025 | |
| NCT05959694 | Recruiting | Phase 1/Phase 2 | A Clinical Trial on the Safety and Efficacy of TQB3909 Tablets in Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) . | October 11, 2023 | June 2026 |
| NCT03128879 | Recruiting | Phase 2 | Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL | June 16, 2017 | June 1, 2025 |
| NCT04269902 | Recruiting | Phase 3 | Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | March 2, 2021 | October 1, 2028 |
| NCT04282018 | Recruiting | Phase 1/Phase 2 | Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | May 25, 2020 | December 31, 2025 |
| NCT04282811 | Recruiting | Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy | July 24, 2020 | October 31, 2025 | |
| NCT05326308 | Recruiting | Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma | April 26, 2022 | April 2027 | |
| NCT04358458 | Terminated | Phase 1/Phase 2 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | March 24, 2020 | July 28, 2023 |
| NCT02612311 | Terminated | Phase 3 | Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia | November 19, 2015 | February 22, 2023 |
| NCT01173679 | Terminated | Phase 2 | Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory CLL and SLL | July 2010 | January 2015 |
| NCT02656303 | Terminated | Phase 2 | A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | January 7, 2016 | July 11, 2022 |
| NCT01090414 | Terminated | Phase 1/Phase 2 | An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study | March 22, 2010 | June 18, 2018 |
| NCT02784834 | Terminated | Phase 1 | Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL | June 2016 | February 2019 |
| NCT01076556 | Terminated | Phase 1 | Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | April 2010 | |
| NCT02877082 | Terminated | Phase 2 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | September 2016 | July 2017 |
| NCT01013961 | Terminated | Phase 2 | Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia | April 27, 2011 | April 14, 2015 |
| NCT02991898 | Terminated | Phase 2 | Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies | February 16, 2017 | June 20, 2019 |
| NCT03037645 | Terminated | Phase 1/Phase 2 | Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers | April 28, 2017 | August 31, 2020 |
| NCT03153514 | Terminated | Phase 2 | Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter's Transformation Requiring Allogeneic Stem Cell Transplantation | November 13, 2017 | June 6, 2019 |
| NCT01010568 | Terminated | Phase 2 | Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL) | April 2010 | August 2014 |
| NCT03195010 | Terminated | Phase 2 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia | June 9, 2017 | December 21, 2018 |
| NCT01005979 | Terminated | Phase 1 | A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL) | July 2010 | |
| NCT03207256 | Terminated | Phase 2 | Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials | August 9, 2017 | June 24, 2022 |
| NCT00963495 | Terminated | Phase 1 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy | August 2009 | September 2013 |
| NCT00022971 | Terminated | Phase 1 | Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia | August 15, 2001 | March 17, 2017 |
| NCT00949988 | Terminated | Phase 1/Phase 2 | A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia | May 2009 | April 2012 |
| NCT00946023 | Terminated | Phase 2 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | July 2009 | July 17, 2013 |
| NCT00942409 | Terminated | Phase 2 | Study of Repeat Intranodal Injections of Ad-ISF35 | June 2009 | July 2014 |
| NCT03379051 | Terminated | Phase 1/Phase 2 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | March 27, 2018 | June 16, 2022 |
| NCT00916045 | Terminated | Phase 2 | Pilot Study of Unrelated Cord Blood Transplantation | September 2009 | March 2012 |
| NCT03436771 | Terminated | Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product | February 19, 2018 | July 20, 2018 | |
| NCT00899431 | Terminated | Phase 2 | Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) | May 6, 2009 | October 7, 2018 |
| NCT00899353 | Terminated | Phase 2 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | August 2008 | October 2012 |
| NCT03514017 | Terminated | Phase 2 | Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia | May 31, 2019 | May 16, 2023 |
| NCT00849524 | Terminated | Phase 2 | Study of Repeat Intranodal Injection of Memgen's Cancer Vaccine, Ad-ISF35, in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | January 2009 | July 2014 |
| NCT00836043 | Terminated | Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia | October 2008 | April 2009 | |
| NCT03572634 | Terminated | Phase 1/Phase 2 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | June 10, 2019 | January 21, 2020 |
| NCT03601819 | Terminated | Phase 1 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | May 15, 2019 | July 17, 2020 |
| NCT03615105 | Terminated | Phase 2 | Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors | July 25, 2018 | March 6, 2024 |
| NCT00801060 | Terminated | Phase 2 | Evaluation of Safety and Efficacy of Fludarabine, Cyclophosphamide, and Rituximab (FCR) +/- Lumiliximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | February 2008 | September 2010 |
| NCT00792831 | Terminated | Phase 2 | Phase II Study of Histone-deacetylase Inhibitor ITF2357 in Refractory/Relapsed Lymphocytic Leukemia | February 2008 | April 2009 |
| NCT00771602 | Terminated | Phase 2 | Alemtuzumab + Rituximab Consolidation in CLL | August 2008 | December 2010 |
| NCT03801525 | Terminated | Phase 2/Phase 3 | Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | May 16, 2019 | December 20, 2022 |
| NCT00674427 | Terminated | Phase 1 | Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant | January 2008 | January 2012 |
| NCT00596336 | Terminated | Phase 2 | Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients | October 2007 | March 15, 2017 |
| NCT04016805 | Terminated | Phase 2 | Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | August 5, 2019 | May 22, 2022 |
| NCT00594308 | Terminated | N/A | In-Vivo Activated T-Cell Depletion to Prevent GVHD | October 2007 | |
| NCT00587847 | Terminated | N/A | Campath Maintenance in Chronic Lymphocytic Leukemia | August 2005 | November 2009 |
| NCT04149821 | Terminated | Phase 2 | Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy | February 10, 2021 | June 9, 2022 |
| NCT00558961 | Terminated | Phase 1/Phase 2 | Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients | October 2005 | April 2009 |
| NCT04155840 | Terminated | Phase 2 | Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | January 31, 2020 | March 16, 2021 |
| NCT00543114 | Terminated | Phase 1 | Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL | October 2007 | December 2012 |
| NCT04160195 | Terminated | Phase 1 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | December 20, 2019 | June 11, 2021 |
| NCT04163718 | Terminated | Phase 2 | TGR-1202 (Umbralisib) in Treatment Naïve Patients With Chronic Lymphocytic Leukemia (CLL) | November 12, 2019 | October 19, 2022 |
| NCT04189952 | Terminated | Phase 2 | Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma | September 22, 2020 | March 1, 2022 |
| NCT00524667 | Terminated | Phase 2 | HDAC Inhibitor Valproic Acid as an Effective Therapy for Chronic Lymphocytic Leukemia | January 2008 | July 2011 |
| NCT04245722 | Terminated | Phase 1 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | March 19, 2020 | September 27, 2023 |
| NCT00499239 | Terminated | Phase 1/Phase 2 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | July 2007 | October 2010 |
| NCT04342117 | Terminated | Observational Trial of Real-World Treatment Utilization and Effectiveness of PI3K-inhibitors in CLL/SLL and FL | April 23, 2020 | December 31, 2020 | |
| NCT04419389 | Terminated | Phase 1/Phase 2 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | March 2, 2021 | August 24, 2021 |
| NCT00496132 | Terminated | Phase 1/Phase 2 | A Trial of the Safety of Escalating Doses of PRO131921 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | August 27, 2007 | June 17, 2009 |
| NCT00416910 | Terminated | Phase 3 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | July 1999 | September 2007 |
| NCT04504708 | Terminated | Phase 1/Phase 2 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | February 17, 2021 | July 8, 2022 |
| NCT00413478 | Terminated | Phase 2 | 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia | September 2006 | November 2014 |
| NCT00391066 | Terminated | Phase 2 | Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) | November 2006 | December 2010 |
| NCT04595851 | Terminated | N/A | Pharmacists Coordinated Care Oncology Model (PCOM) for Patients Taking Oral Anti-cancer Medications | March 26, 2021 | July 14, 2022 |
| NCT00319930 | Terminated | Phase 1 | Phase 1, Dose-Escalation, Pharmacodynamic Study of IV CNF1010 in ZAP-70 Positive CLL | May 2005 | May 2007 |
| NCT00276159 | Terminated | Phase 2 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | January 2006 | November 2008 |
| NCT00234481 | Terminated | Phase 1 | Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia | ||
| NCT00183950 | Terminated | Phase 1/Phase 2 | Study of Noscapine for Patients With Low Grade Non Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Refractory to Chemotherapy | March 2000 | December 2006 |
| NCT00151736 | Terminated | Phase 2 | Safety and Efficacy of SDX-101 (R-Etodolac) in Combination With Chlorambucil, and That of Chlorambucil Alone, in Patients With Chronic Lymphocytic Leukemia (CLL) | September 2004 | February 2008 |
| NCT00108108 | Terminated | Phase 1 | Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy | April 2005 | June 2008 |
| NCT00100711 | Terminated | Phase 2 | Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | October 2004 | |
| NCT00100152 | Terminated | Phase 1 | A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013) | February 2005 | October 2006 |
| NCT01728207 | Terminated | Phase 1 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | March 2013 | March 2017 |
| NCT01744912 | Terminated | Phase 1 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | November 21, 2012 | February 7, 2014 |
| NCT01796470 | Terminated | Phase 2 | Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | June 20, 2013 | December 22, 2016 |
| NCT01799889 | Terminated | Phase 2 | Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies | March 14, 2013 | January 30, 2020 |
| NCT04978779 | Terminated | Phase 1 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | December 16, 2021 | May 26, 2023 |
| NCT00081887 | Terminated | Phase 1 | Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia | May 2004 | June 2007 |
| NCT01944943 | Terminated | Phase 2 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia | February 2013 | October 2014 |
| NCT01980875 | Terminated | Phase 3 | Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia | April 21, 2015 | May 13, 2016 |
| NCT01980888 | Terminated | Phase 3 | Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia | February 5, 2014 | June 16, 2016 |
| NCT05107856 | Terminated | Phase 1 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | March 22, 2022 | January 19, 2024 |
| NCT02034227 | Terminated | Phase 1/Phase 2 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia | April 2012 | June 2014 |
| NCT02046928 | Terminated | Phase 2 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | February 2014 | March 2016 |
| NCT01659021 | Terminated | Phase 3 | Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia | December 4, 2012 | August 15, 2018 |
| NCT02109224 | Terminated | Phase 1 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | September 2014 | July 2015 |
| NCT01649791 | Terminated | N/A | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia | January 2010 | October 2014 |
| NCT01644253 | Terminated | Phase 1 | Phase 1b Safety and Efficacy Study of TRU-016 | September 2012 | April 21, 2021 |
| NCT01629511 | Terminated | Phase 1/Phase 2 | Allogeneic Stem Cell Transplant for CLL | November 21, 2012 | April 25, 2018 |
| NCT01625741 | Terminated | Phase 2 | Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy | July 2012 | May 2015 |
| NCT02200848 | Terminated | Phase 1 | Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | April 2014 | August 1, 2017 |
| NCT02231853 | Terminated | Phase 1 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections | September 3, 2014 | December 29, 2017 |
| NCT01610999 | Terminated | Phase 1 | Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell Transplantation | July 2013 | December 2015 |
| NCT02258555 | Terminated | Phase 1 | Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma | January 2015 | August 2015 |
| NCT01600053 | Terminated | Phase 2 | Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia | November 2011 | May 2014 |
| NCT01585688 | Terminated | Phase 1/Phase 2 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | August 2012 | October 2017 |
| NCT01539291 | Terminated | Phase 3 | Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512) | October 3, 2012 | June 29, 2018 |
| NCT01532635 | Terminated | Phase 2 | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives | March 2012 | May 2013 |
| NCT01510756 | Terminated | Phase 2 | Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL) | December 2011 | December 2014 |
| NCT01500161 | Terminated | Phase 2 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | November 2011 | November 2013 |
| NCT01465230 | Terminated | Phase 2 | Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia | March 2012 | November 2013 |
| NCT02440685 | Terminated | Phase 1/Phase 2 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | May 2015 | July 2018 |
| NCT01403246 | Terminated | Phase 1/Phase 2 | Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | November 2011 | January 2015 |
| NCT01397149 | Terminated | Phase 1/Phase 2 | Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG) | October 2011 | November 2014 |
| NCT00038818 | Terminated | N/A | CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation | May 2001 | December 2002 |
| NCT01352312 | Terminated | Phase 1 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | May 25, 2011 | May 10, 2018 |
| NCT01300611 | Terminated | Phase 1 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation | January 2011 | December 2020 |
| NCT02557516 | Terminated | Phase 1/Phase 2 | Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL | November 9, 2015 | September 25, 2019 |
| NCT03495492 | Unknown status | N/A | Chronic Lymphocytic Leukemia Responds to Dermal Chelation | December 1, 2018 | March 1, 2019 |
| NCT04682808 | Unknown status | Phase 1 | A Study of FCN-338 in Patients With Chronic CLL/SLL | January 15, 2021 | June 1, 2024 |
| NCT05145101 | Unknown status | Pneumococcal Vaccination in Patients With Chronic Lymphocytic Leukaemia | May 7, 2020 | March 31, 2022 | |
| NCT01051115 | Unknown status | Phase 2 | Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease | October 2008 | January 2016 |
| NCT02892695 | Unknown status | Phase 1/Phase 2 | PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma | September 2016 | September 2019 |
| NCT01346020 | Unknown status | Genomic Analysis of Patients With Chronic Lymphocytic Leukemia | April 2010 | ||
| NCT01657955 | Unknown status | Phase 3 | Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia | January 2011 | December 2013 |
| NCT02819583 | Unknown status | Phase 1/Phase 2 | CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | October 2016 | September 2019 |
| NCT00337519 | Unknown status | Phase 2 | Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia | January 2003 | April 2009 |
| NCT04952974 | Unknown status | B-cell Chronic Lymphoid Malignancies Markers | June 14, 2021 | March 30, 2023 | |
| NCT04370457 | Unknown status | N/A | MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies | January 1, 2021 | September 30, 2022 |
| NCT02991638 | Unknown status | Phase 3 | Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers | November 1, 2016 | June 2021 |
| NCT00022880 | Unknown status | Phase 1 | Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia | July 1999 | |
| NCT01521689 | Unknown status | Phase 2 | Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment | December 2011 | June 2015 |
| NCT02156726 | Unknown status | Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project | March 2011 | July 2015 | |
| NCT04094051 | Unknown status | Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice | October 1, 2019 | December 31, 2021 | |
| NCT05371392 | Unknown status | ITGA4 Gene Methylation Status in Chronic Lymphocytic Leukemia | July 1, 2022 | October 1, 2023 | |
| NCT01849939 | Unknown status | Phase 2 | Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia | September 2012 | September 2017 |
| NCT04059081 | Unknown status | Phase 2 | A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment | July 9, 2019 | July 8, 2022 |
| NCT05410041 | Unknown status | Phase 1 | Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies | May 25, 2022 | May 2024 |
| NCT03971565 | Unknown status | Evaluation of the Redox Profiles of Healthy and Pathological B Cells in Patients With Chronic Lymphocytic Leukemia | March 19, 2019 | March 18, 2021 | |
| NCT02851589 | Unknown status | Phase 1/Phase 2 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | July 2016 | November 2019 |
| NCT00598624 | Unknown status | Phase 2 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) | September 2005 | December 2010 |
| NCT00628238 | Unknown status | Phase 2 | Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) | February 2008 | July 2011 |
| NCT02507479 | Unknown status | Phase 2 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | September 2015 | July 2019 |
| NCT03881592 | Unknown status | Real-World Data Study Focused on Chronic Lymphocytic Leukemia (CLL) Patient Treatment Options and Their Effectiveness | November 1, 2018 | September 2019 | |
| NCT02981745 | Unknown status | Phase 1/Phase 2 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | April 1, 2017 | December 2018 |
| NCT03847727 | Unknown status | Bendamustine and Rituximab (BR) as Induction and Maintenance in Relapsed and Refractory Chronic Lymphocytic Leukemia | December 3, 2013 | December 3, 2020 | |
| NCT01295593 | Unknown status | Phase 1/Phase 2 | Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL) | December 2010 | April 2013 |
| NCT02456350 | Unknown status | Phase 1 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | April 2015 | December 2019 |
| NCT03191773 | Unknown status | Phase 1/Phase 2 | A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies | June 30, 2017 | December 31, 2020 |
| NCT03150849 | Unknown status | C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia | July 1, 2017 | December 1, 2019 | |
| NCT03633045 | Unknown status | Observational Study of Ibrutinib Use in CLL | September 1, 2018 | April 30, 2022 | |
| NCT04796675 | Unknown status | Phase 1 | Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies | April 10, 2021 | March 10, 2024 |
| NCT03088709 | Unknown status | Phase 2 | Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | January 18, 2017 | January 31, 2022 |
| NCT04814004 | Unknown status | Phase 1 | Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors | March 19, 2021 | April 1, 2024 |
| NCT00109356 | Unknown status | Phase 1/Phase 2 | Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia | March 2005 | March 2007 |
| NCT00131313 | Unknown status | Phase 4 | Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia. | January 2003 | April 2009 |
| NCT01670812 | Unknown status | Phase 3 | Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia | January 2012 | June 2014 |
| NCT00810680 | Unknown status | N/A | Study of Efficacy and Safety of Valproic Acid in Chronic Lymphocytic Leukemia (CLL) | September 2008 | March 2009 |
| NCT00868478 | Unknown status | Phase 1/Phase 2 | The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | April 2009 | April 2012 |
| NCT04862806 | Unknown status | N/A | Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL | February 1, 2021 | March 2022 |
| NCT04691765 | Unknown status | Phase 1 | Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients | May 1, 2021 | December 2022 |
| NCT00676871 | Withdrawn | Phase 1/Phase 2 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) | June 2008 | June 2011 |
| NCT00758693 | Withdrawn | Phase 2 | Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL) | October 2008 | July 2010 |
| NCT00800566 | Withdrawn | Phase 1 | Oral Clofarabine in Chronic Lymphocytic Leukemia (CLL) | November 2008 | April 2009 |
| NCT01659047 | Withdrawn | Phase 2 | A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia | August 2012 | December 2015 |
| NCT03639324 | Withdrawn | Phase 1 | Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL | October 2, 2020 | October 18, 2021 |
| NCT02371590 | Withdrawn | Phase 2 | Lenalidomide and Obinutuzumab for Previously Untreated CLL | February 2018 | December 2022 |
| NCT00829647 | Withdrawn | Phase 1/Phase 2 | A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia | January 2009 | March 1, 2016 |
| NCT00872976 | Withdrawn | Phase 1 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | May 2009 | December 2011 |
| NCT05521178 | Withdrawn | Cardiotoxicities in Patients Receiving BTKi | May 2024 | January 1, 2028 | |
| NCT03438344 | Withdrawn | Phase 2 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant | December 2018 | December 2021 |
| NCT03370185 | Withdrawn | Phase 2 | Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma | February 12, 2018 | March 2021 |
| NCT00962715 | Withdrawn | Phase 1/Phase 2 | Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia | April 2011 | |
| NCT05465876 | Withdrawn | Phase 2 | Passive Antibodies Against COVID-19 With EVUSHELD in Vaccine Non-responsive CLL | October 2023 | October 2025 |
| NCT01271283 | Withdrawn | Phase 2 | Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | December 2010 | August 2011 |
| NCT01163201 | Withdrawn | Phase 1/Phase 2 | T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies | January 2014 | January 2015 |
| NCT04694560 | Withdrawn | A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | December 22, 2020 | March 6, 2023 | |
| NCT01069432 | Withdrawn | Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia | May 2010 | February 2011 | |
| NCT04665115 | Withdrawn | Phase 2 | Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) | November 23, 2020 | July 22, 2022 |
| NCT04660045 | Withdrawn | Phase 2 | Early Intervention With Acalabrutinib in Patients With High Risk CLL | May 2022 | June 2026 |
| NCT00093314 | Withdrawn | Phase 1/Phase 2 | HuMax-CD20 in Chronic Lymphocytic Leukemia | October 2004 | January 2007 |
| NCT02993536 | Withdrawn | Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab | November 2015 | ||
| NCT01739491 | Withdrawn | A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia | October 2014 | November 2016 | |
| NCT02640833 | Withdrawn | Phase 1 | A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor | July 2016 | February 2021 |
| NCT02677948 | Withdrawn | Phase 1/Phase 2 | Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | October 2016 | October 2018 |
| NCT02611908 | Withdrawn | Phase 1 | Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib. | June 2016 | November 2020 |
| NCT04282174 | Withdrawn | Phase 2 | CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies | September 2022 | March 1, 2030 |
| NCT04043845 | Withdrawn | Phase 1 | ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies | February 3, 2020 | February 3, 2020 |
| NCT03943342 | Withdrawn | Phase 2 | Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance | March 11, 2020 | July 20, 2021 |
| NCT05037669 | Withdrawn | Phase 1 | Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma | July 2022 | January 2038 |
- Disase Synonym (Disease Ontology)
- B-cell chronic lymphoid leukemia
- Exact Synonym (Disease Ontology)
- B-cell chronic lymphocytic leukaemia
- Exact Synonym (Disease Ontology)
- B-cell chronic lymphocytic leukemia
- Exact Synonym (Disease Ontology)
- chronic lymphatic leukaemia
- Exact Synonym (Disease Ontology)
- chronic lymphatic leukemia
- Exact Synonym (Disease Ontology)
- chronic lymphocytic leukaemia
- Exact Synonym (Disease Ontology)
- CLL
- Exact Synonym (Disease Ontology)
- lymphoplasmacytic leukaemia
- Exact Synonym (Disease Ontology)
- lymphoplasmacytic leukemia
- Disase is a (Disease Ontology)
- DOID:1037
- Cross Reference ID (Disease Ontology)
- EFO:0000095
- Cross Reference ID (Disease Ontology)
- GARD:6104
- Cross Reference ID (Disease Ontology)
- ICD10CM:C91.10
- Cross Reference ID (Disease Ontology)
- ICD9CM:204.1
- Cross Reference ID (Disease Ontology)
- MESH:D015451
- Cross Reference ID (Disease Ontology)
- MIM:109543
- Cross Reference ID (Disease Ontology)
- MIM:151400
- Cross Reference ID (Disease Ontology)
- MIM:609630
- Cross Reference ID (Disease Ontology)
- MIM:612557
- Cross Reference ID (Disease Ontology)
- MIM:612558
- Cross Reference ID (Disease Ontology)
- MIM:612559
- Cross Reference ID (Disease Ontology)
- NCI:C3163
- Cross Reference ID (Disease Ontology)
- ORDO:67038
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:51092000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023434